LIMK2

Across TCGA pan-cancer cohorts, LIMK2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LIMK2 data layer compared with 15 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LIMK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LIMK2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where LIMK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.895	0.267	.003	18	view →
CCRCC	OS	Quartile	III,IV	0.355	0.786	.007	16	view →
UCEC	OS	Median	III,IV	1.000	0.433	.007	16	view →
PDAC	DFS	Median	II,III,IV	0.264	0.440	.020	8	view →
COAD	DFS	Median	III,IV	0.891	1.000	.041	6	view →
GBM	OS	Tertile	All	0.302	0.536	.040	2	view →
LSCC	OS	Tertile	All	1.000	0.795	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LIMK2–HNSC (DFS)

Open the HNSC breakdown →